(secondQuint)Phase I Study of Heme Arginate With or Without Tin Mesoporphyrin in Patients With Acute Attacks of Porphyria.

 PROTOCOL OUTLINE: This is an randomized, unblinded, multicenter study.

 Patients are randomized to receive heme arginate alone or both heme arginate and tin mesoporphyrin.

 Patients receive a single intravenous dose of tin mesoporphyrin immediately before the first dose of heme arginate.

 Heme arginate is administered daily for 4 days.

 Patients are followed at 3 and 6 days after treatment.

.

 Phase I Study of Heme Arginate With or Without Tin Mesoporphyrin in Patients With Acute Attacks of Porphyria@highlight

OBJECTIVES: I.

 Evaluate the efficacy of tin mesoporphyrin in patients with acute porphyria attacks who are also treated with a standard course of heme arginate.

 II.

 Evaluate the safety and tolerability of tin mesoporphyrin when administered to these patients.

